Literature DB >> 28593892

Neonatal Hypoglycemia: Risk Factors and Outcomes.

Orhideja Stomnaroska1, Elizabeta Petkovska2, Snezana Jancevska2, Dragan Danilovski3.   

Abstract

BACKGROUND AND AIMS: Severe neonatal hypoglycemia (HG) leads to neurologic damage, mental retardation, epilepsy, personality disorders, impaired cardiac performance and muscle weakness. We aimed to assess the clinical characteristics of children with hypoglycemia in a random population of newborns. PATIENTS, METHODS AND
RESULTS: We investigated 84 patients (M:F=35:48) born at the University Clinic for Gynecology and Obstetrics in Skopje (hospitalized in the NICU) who were found to have hypoglycemia. In total 89.25% of the babies were premature. The mean birth weight was 1795.95 +/596.08 grams, the mean birth length was 41.92+/- 4.62 cm, while the mean gestational age was 33.05±3.19 weeks. 32 children (38.08%) were very low birth weight (<1500g), 38 (45.22%) were low birth weight (1500-2500g), while there were 8 children (9.52%) appropriate for age BW and no high BW for age patients (>4000 g). HG duration was 2.42+/-2.41 hours. In the group as a whole, hypoxic-ischemic encephalopathy (HIE) was found in 3 children (3.57%), infections in 22 (26.18%), respiratory distress syndrome (RDS) in 9 patients (10.62%), intracranial haemorrhage in 2 patients (2.38%). There were no inborn errors of metabolism. There were two deaths (2.38%).
CONCLUSION: Neonatal HG is a significant factor in the overall neonatal mortality. HG can also cause severe invalidity. We found that infections, LBW and low gestational age were most commonly associated with neonatal HG. However the Spearman test showed weak direct correlation, without statistical significance. Neonatal HG requires complex and team interaction of prenatal and postnatal approaches to reduce the incidence of seizures, their consequences and the overall mortality. Special consideration is to be taken in measures that avoid neonatal infections, HIE, LBW and low gestational age. Further studies on a larger population are needed to fully understand and prevent the phenomenon of HG in newborns.

Entities:  

Keywords:  HIE; co-morbidities; low birth weight; mortality; neonatal hypoglycemia

Mesh:

Substances:

Year:  2017        PMID: 28593892     DOI: 10.1515/prilozi-2017-0013

Source DB:  PubMed          Journal:  Pril (Makedon Akad Nauk Umet Odd Med Nauki)        ISSN: 1857-9345


  5 in total

Review 1.  The Risk for Neonatal Hypoglycemia and Bradycardia after Beta-Blocker Use during Pregnancy or Lactation: A Systematic Review and Meta-Analysis.

Authors:  Rosalie de Bruin; Sarah L van Dalen; Shamaya J Franx; Viraraghavan V Ramaswamy; Sinno H P Simons; Robert B Flint; Gerbrich E van den Bosch
Journal:  Int J Environ Res Public Health       Date:  2022-08-04       Impact factor: 4.614

2.  Lifestyle intervention during pregnancy in patients with gestational diabetes mellitus and the risk of neonatal hypoglycemia: A systematic review and meta-analysis.

Authors:  Ya-Hai Wang; Huan-Huan Zhou; Zhibin Nie; Jingwang Tan; Zicheng Yang; Shengliang Zou; Zheng Zhang; Yu Zou
Journal:  Front Nutr       Date:  2022-07-28

Review 3.  Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review.

Authors:  Dylan van de Vusse; Paola Mian; Sam Schoenmakers; Robert B Flint; Willy Visser; Karel Allegaert; Jorie Versmissen
Journal:  Eur J Clin Pharmacol       Date:  2022-09-15       Impact factor: 3.064

4.  Risk for neonatal hypoglycaemia and bradycardia after beta-blocker use during pregnancy or lactation: a systematic review and meta-analysis protocol.

Authors:  Rosalie de Bruin; Sarah L van Dalen; Shamaya J Franx; Sinno Hp Simons; Robert B Flint; Gerbrich E van den Bosch
Journal:  BMJ Open       Date:  2022-08-25       Impact factor: 3.006

5.  Identifying risk effectors involved in neonatal hypoglycemia occurrence.

Authors:  Tian Zhao; Qiying Liu; Man Zhou; Wei Dai; Yin Xu; Li Kuang; Yaqiong Ming; Guiyu Sun
Journal:  Biosci Rep       Date:  2020-03-27       Impact factor: 3.840

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.